Specific molecular signatures of non-tumor liver tissue may predict a risk of hepatocarcinogenesis

Cancer Science

Volumn 105, Issue 7, 2014, Pages 749-754

  Utsunomiya, Tohru ^a   Shimada, Mitsuo ^a   Morine, Yuji ^a   Tajima, Atsushi ^a   Imoto, Issei ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Carcinogenesis; DNA methylation; Epigenetics; Hepatocellular carcinoma; Microarray

Indexed keywords

HEPATITIS B CORE ANTIBODY;

CANCER PROGNOSIS; CANCER RISK; CHRONIC LIVER DISEASE; CLINICAL FEATURE; CPG ISLAND; DNA METHYLATION; EPIGENETICS; FOLLOW UP; GENE EXPRESSION PROFILING; HEPATITIS C VIRUS; HUMAN; LIVER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR GENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

CARCINOGENESIS; DNA METHYLATION; EPIGENETICS; HEPATOCELLULAR CARCINOMA; MICROARRAY;

CARCINOMA, HEPATOCELLULAR; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MICRORNAS;

EID: 84904333634     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12431     Document Type: Review

References (66)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6: 674-87.
3. Sherlock S. Viruses and hepatocellular carcinoma. Gut 1994; 35: 828-32.
4. Sakamoto M. Early HCC: diagnosis and molecular markers. J Gastroenterol 2009; 44: 108-11.
5. Iizuka N, Oka M, Yamada Okabe H et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003; 361: 923-9.
6. Yoshioka S, Takemasa I, Nagano H et al. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur J Cancer 2009; 45: 881-9.
7. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-7.
8. Takenaka K, Adachi E, Nishizaki T et al. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology 1994; 19: 889-94.
9. Kim JW, Ye Q, Forgues M et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatology 2004; 39: 518-27.
10. Utsunomiya T, Shimada M, Imura S et al. Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol 2010; 45: 146-52.
11. Tanaka S, Mogushi K, Yasen M et al. Oxidative stress pathways in noncancerous human liver tissue to predict hepatocellular carcinoma recurrence: a prospective, multicenter study. Hepatology 2011; 54: 1273-81.
12. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-8.
13. Shen L, Kondo Y, Rosner GL et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97: 1330-8.
14. Chang YL, Wu CT, Lin SC, Hsiao CF, Jou YS, Lee YC. Clonality and prognostic implications of p53 and epidermal growth factor receptor somatic aberrations in multiple primary lung cancers. Clin Cancer Res 2007; 13: 52-8.
15. Lou C, Du Z, Yang B, Gao Y, Wang Y, Fang S. Aberrant DNA methylation profile of hepatocellular carcinoma and surgically resected margin. Cancer Sci 2009; 100: 996-1004.
16. Utsunomiya T, Okamoto M, Wakiyama S et al. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann Surg Oncol 2006; 13: 947-54.
17. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004.
18. Tsuchiya M, Parker JS, Kono H et al. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 2010; 9: 74.
19. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
20. van Rooij E, Sutherland LB, Liu N et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006; 103: 18255-60.
21. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res 2006; 66: 10843-8.
22. Schmittgen TD. Regulation of microRNA processing in development, differentiation and cancer. J Cell Mol Med 2008; 12: 1811-9.
23. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
24. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174: 1131-8.
25. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-47.
26. Jiang J, Gusev Y, Aderca I et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res 2008; 142: 419-27.
27. Budhu A, Jia HL, Forgues M et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008; 473: 897-907.
28. Sato F, Hatano E, Kitamura K et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria. PLoS One 2011; 61: e16435.
29. Viswanathan SR, Powers JT, Einhorn W et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 2009; 417: 843-8.
30. Wong CM, Wong CC, Lee JM, Fan DN, Au SL, Ng IO. Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012; 55: 1453-61.
31. Murakami Y, Tamori A, Itami S et al. The expression level of miR-18b in hepatocellular carcinoma is associated with the grade of malignancy and prognosis. BMC Cancer 2013; 13: 99.
32. Utsunomiya T, Ishikawa D, Asanoma M et al. Specific miRNA expression profiles of non-tumor liver tissue predict a risk for recurrence of hepatocellular carcinoma. Hepatol Res 2013; doi: 10.1111/hepr.12164 [Epub ahead of print].
33. Davidson LA, Wang N, Shah MS, Lupton JR, Ivanov I, Chapkin RS. n-3 Polyunsaturated fatty acids modulate carcinogen-directed non-coding microRNA signatures in rat colon. Carcinogenesis 2009; 30: 2077-84.
34. Jiao LR, Frampton AE, Jacob J et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One 2012; 7: e32068.
35. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-93.
36. Matsuzaki K, Deng G, Tanaka H, Kakar S, Miura S, Kim YS. The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 2005; 11: 8564-9.
37. Lin CH, Hsieh SY, Sheen IS et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001; 61: 4238-43.
38. Shen L, Ahuja N, Shen Y et al. DNA methylation and environmental exposures in human hepatocellular car- cinoma. J Natl Cancer Inst 2002; 94: 755-61.
39. Calvisi DF, Ladu S, Gorden A et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 2007; 117: 2713-22.
40. Gao W, Kondo Y, Shen L et al. Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis 2008; 29: 1901-10.
41. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010; 5: e9749.
42. Tao R, Li J, Xin J et al. Methylation profile of single hepatocytes derived from hepatitis B virus-related hepatocellular carcinoma. PLoS One 2011; 6: e19862.
43. Formeister EJ, Tsuchiya M, Fujii H, Shpyleva S, Pogribny IP, Rusyn I. Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma. Mutat Res 2010; 692: 26-33.
44. Um TH, Kim H, Oh BK et al. Aberrant CpG island hypermethylation in dysplastic nodules and early HCC of hepatitis B virus-related human multistep hepatocarcinogenesis. J Hepatol 2011; 54: 939-47.
45. Archer KJ, Mas VR, Maluf DG, Fisher RA. High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCVassociated hepatocellular carcinoma. Mol Genet Genomics 2010; 283: 341-9.
46. Kanai Y, Ushijima S, Tsuda H, Sakamoto M, Sugimura T, Hirohashi S. Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. Jpn J Cancer Res 1996; 87: 1210-7.
47. Arai E, Ushijima S, Gotoh M et al. Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer 2009; 125: 2854-62.
48. Nagashio R, Arai E, Ojima H, Kosuge T, Kondo Y, Kanai Y. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage. Int J Cancer 2011; 129: 1170-9.
49. Kanai Y. Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 2010; 101: 36-45.
50. Shin SH, Kim BH, Jang JJ, Suh KS, Kang GH. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci 2010; 25: 1152-9.
51. Neumann O, Kesselmeier M, Geffers R et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 2012; 56: 1817-27.
52. Shen J, Wang S, Zhang YJ et al. Genome-wide DNA methylation profiles in hepatocellular carcinoma. Hepatology 2012; 55: 1799-808.
53. Ammerpohl O, Pratschke J, Schafmayer C et al. Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 2012; 130: 1319-28.
54. Song MA, Tiirikainen M, Kwee S, Okimoto G, Yu H, Wong LL. Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma. PLoS One 2013; 8: e55761.
55. Shen J, Wang S, Zhang YJ et al. Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using Infinium HumanMethylation 450 BeadChips. Epigenetics 2013; 8: 34-43.
56. Chiba T, Yokosuka O, Fukai K et al. Identification and investigation of methylated genes in hepatoma. Eur J Cancer 2005; 41: 1185-94.
57. Feng Q, Stern JE, Hawes SE, Lu H, Jiang M, Kiviat NB. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol 2010; 88: 287-92.
58. Lambert MP, Paliwal A, Vaissière T et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol 2011; 54: 705-15.
59. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008; 47: 908-18.
60. Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology 2012; 56: 994-1003.
61. Utsunomiya T, Shimada M. Molecular characteristics of non-cancerous liver tissue in non-B non-C hepatocellular carcinoma. Hepatol Res 2011; 41: 711-21.
62. Utsunomiya T, Shimada M, Kudo M. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact. Ann Surg 2014; 259: 336-45.
63. Kinoshita M, Numata S, Tajima A, Shimodera S, Imoto I, Ohmori T. Plasma total homocysteine is associated with DNA methylation in patients with schizophrenia. Epigenetics 2013; 8: 584-90.
64. Bibikova M, Barnes B, Tsan C et al. High density DNA methylation array with single CpG site resolution. Genomics 2011; 98: 288-95.
65. Kulis M, Queirós AC, Beekman R, Martín-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta 2013; 1829: 1161-74.
66. Chen YA, Lemire M, Choufani S et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics 2013; 8: 203-9.